Interleukins

Abstract

The interleukins are a major class of biologically active protein mediators, known as cytokines, that following release from activated cells bind to specific cell surface receptors to induce growth and differentiating functions in target cells. Extensive studies into their genes, structures, receptors, signal transduction pathways and activities in experimental cell cultures have provided considerable knowledge leading to their molecular and biological characterisation. Fundamental findings are that they are mostly pleiotropic mediators, that is, act on more than one cell type or at different stages of cellular development, and stimulate multiple activities, especially where acting in combinations of two or more interleukins. Their production as essentially pure recombinant proteins has enabled studies in experimental model systems to determine whether their activities could be of clinical benefit, or harmful. Subsequently, several interleukins and their antagonists have been evaluated for clinical efficacy and safety in clinical studies, and have yielded promising, though not fully effective, therapeutic treatments for patients with cancer and autoinflammatory diseases. In this article, the molecular characteristics of interleukins, their cognate receptors and intracellular signalling pathways, their biological activities and their potential clinical uses are briefly described.

Key Concepts:

  • Interleukins are a broad class of biologically active proteins with hormone‐like actions that regulate the development, differentiation and functions of cells of the immune and haematopoietic systems.

  • The activities of interleukins are mediated via cell surface receptors.

  • Binding of interleukins to receptors triggers gene induction via the activation of intracellular signal transduction pathways.

  • Interleukins exhibit complex biological interactions, both among themselves and with other molecular mediators, in vivo.

  • The proinflammatory and immune‐stimulatory activities of interleukins are essential for host defence against pathogens.

  • Interleukins can be ‘two‐edged swords’, being largely beneficial to the host at low concentrations but deleterious and toxic at high concentrations.

  • The biological properties of interleukins have suggested their potential for development as therapeutic drugs (biopharmaceuticals) against infections and chronic diseases, such as cancer, but so far only a few have proved clinically useful.

  • Antibody and receptor antagonists of interleukins are showing promise for the treatment of autoinflammatory and autoimmune diseases, such as irritable bowel disorders and RA.

Keywords: interleukins; cytokines; receptors; biological activity; therapeutic potential; proinflammatory; immunosuppressive; immune response; antagonists

References

Akira S , Taga T and Kishimoto T (1993) Interleukin-6 in biology and medicine. Advances in Immunology 54: 1–78.

Alber G , Al‐Robaiy S , Kleinschek M et al. (2006) Induction of immunity and inflammation by interleukin‐12 family members. Ernst Schering Research Foundation Workshop 56: 107–127.

Ambrus J Jr , Pippin J , Joseph A et al. (1993) Identification of a cDNA for human high molecular weight B cell growth factor (HMW‐BCGF). Proceedings of the National Academy of Sciences of the USA 90: 6330–6334.

Annunziato F , Cosmi L , Liotta F , Maggi E and Romagnani S (2009) Type 17 T helper cells – origins, features and possible roles in rheumatoid arthritis. Nature Reviews Rheumatology 5: 325–331.

Arend WP , Palmer G and Gabay C (2008) IL‐1, IL‐18 and IL‐33 families of cytokines. Immunological Reviews 223: 20–38.

Aujla SJ and Kolls JK (2009) IL‐22: a critical mediator in mucosal host defense. Journal of Molecular Medicine 87: 451–454.

Azuma YT , Nakajima H and Takeuchi T (2011) IL‐19 as a potential therapeutic in autoimmune and inflammatory diseases. Current Pharmaceutical Design 17: 3776–3780.

Baggiolini M , Dewald B and Moser B (1994) Interleukin‐8 and related chemotactic cytokines – CXC and CC chemokines. Advances in Immunology 55: 97–179.

Banchereau J , Pascual V and O'Garra A (2012) From IL‐2 to IL‐37: the expanding spectrum of anti‐inflammatory cytokines. Nature Immunology 13: 925–931.

Bhattacharjee A , Shukla M , Yakubenko VP et al. (2012) IL‐4 and IL‐13 employ discrete signalling pathways for target gene expression in alternatively activated monocytes/macrophages. Free Radical Biology and Medicine 54: 1–16.

Boraschi D and Dinarello CA (2006) IL‐18 in autoimmunity: a review. European Cytokine Network 17: 224–252.

Boulay J‐L and Paul W (1992) The interleukin‐4‐related lymphokines and their binding to haematopoietin receptors. Journal of Biological Chemistry 267: 20525–20528.

Boyman O and Sprent J (2012) The role of interleukin‐2 during homeostasis and activation of the immune system. Nature Reviews Immunology 12: 180–190.

Broughton SE , Dhagat U , Hercus TR et al. (2012) The GM‐CSF/IL‐3/IL‐5 cytokine receptor family: from ligand recognition to initiation of signalling. Immunological Reviews 250: 271–302.

Budagian V , Bulanova E , Paus R and Bulfone‐Paus (2006) IL‐15/IL‐15 receptor biology: a guided tour through an expanding universe. Cytokine and Growth Factor Reviews 17: 259–280.

Camporeale A and Poli V (2012) IL‐6, IL‐17 and STAT3: a holy trinity in autoimmunity? Frontiers in Bioscience 17: 2306–2326.

Chihara T , Suzu S , Hassan R et al. (2010) IL‐34 and M‐CSF share the receptor Fms but are not identical in biological activity and signal activation. Cell Death and Differentiation 17: 1917–1927.

Cohen J (2012) Inhibition of interleukin‐5 for the treatment of eosinophilic diseases. Discovery Medicine 13: 305–312.

Collison LW , Delgoffe GM , Guy CS et al. (2012) The composition and signalling of the IL‐35 receptor are unconventional. Nature Immunology 13: 290–299.

Corfe SA and Paige CJ (2012) The many roles of IL‐7 in B cell development; mediator of survival, proliferation and differentiation. Seminars in Immunology 24: 198–208.

Cornelissen C , Lüscher-Firzlaff J , Baron JM and Lüscher B (2012) Signaling by IL‐31 and its functional consequences. European Journal of Cell Biology 91: 552–566.

Croce M , Orengo AM , Azzarone B and Ferrini S (2012) Immunotherapeutic applications of IL‐15. Immunotherapy 4: 957–969.

Croxford AL , Mair F and Becher B (2012) IL‐23: one cytokine in control of autoimmunity. European Journal of Immunology 42: 2263–2273.

Cruikshank W and Little F (2008) Interleukin‐16: the ins and outs of regulating T‐cell activation. Critical Reviews in Immunology 28: 467–483.

De Vries JE (1996) Molecular and biological characteristics of interleukin‐13. Chemical Immunology 63: 204–218.

Di Cesare A , Di Meglio P and Nestle FO (2009) The IL‐23/Th17 axis in the immunopathogenesis of psoriasis. Journal of Investigative Dermatology 129: 1339–1350.

Di Sabatino A , Calarota SA , Vidali F , Macdonald TT and Corazza GR (2011) Role of IL‐15 in immune‐mediated and infectious diseases. Cytokine and Growth Factor Reviews 22: 19–33.

Dinarello CA (2009) Immunological and inflammatory functions of the interleukin‐1 family. Annual Review of Immunology 27: 519–550.

Dinarello CA , Arend W , Sims J et al. (2010) IL‐1 family nomenclature. Nature Immunology 11: 973.

Dinarello CA , Simon A and van der Meer JW (2012) Treating inflammation by blocking interleukin‐1 in a broad spectrum of diseases. Nature Reviews Drug Discovery 11: 633–652.

Donnelly RP and Kotenko SV (2010) Interferon‐lambda: a new addition to an old family. Journal of Interferon and Cytokine Research 30: 555–564.

Donnelly RP , Sheikh F , Kotenko SV and Dickensheets H (2004) The expanded family of class II cytokines that share the IL‐10 receptor‐2 (IL‐10R2) chain. Journal of Leukocyte Biology 76: 314–321.

Donnelly RP , Sheikh F , Dickensheets H et al. (2010) Interleukin‐26: an IL‐10‐related cytokine produced by Th17 cells. Cytokine and Growth Factor Reviews 21: 393–401.

Donnelly RP , Dickensheets H and O'Brien TR (2011) Interferon‐lambda and therapy for chronic hepatitis C virus infection. Trends in Immunology 32: 443–450.

Du X and Williams D (1994) Interleukin‐11: a multifunctional growth factor derived from the hematopoietic microenvironment. Blood 83: 2023–2030.

Duvallet E , Semerano L , Assier E , Falgarone G and Boissier MC (2011) Interleukin‐23: a key cytokine in inflammatory diseases. Annals of Medicine 43: 503–511.

Ely LK , Fischer S and Garcia KC (2009) Structural basis of receptor sharing by the interleukin‐17 cytokines. Nature Immunology 10: 1245–1251.

Felaco P , Castellani ML , De Lutiis MA et al. (2009) IL‐32: a newly‐discovered proinflammatory cytokine. Journal of Biological Regulators and Homeostatic Agents 23: 141–147.

Fickenscher H , Hör S , Küpers H et al. (2003) The interleukin‐10 family of cytokines. Trends in Immunology 23: 89–96.

Gaffen SL (2009) Structure and signalling in the IL‐17 receptor family. Nature Reviews Immunology 9: 556–567.

Gaffen SL (2011) Recent advances in the IL‐17 cytokine family. Current Opinion in Immunology 23: 613–619.

Gallagher G (2010) Interleukin‐19: multiple roles in immune regulation and disease. Cytokine and Growth Factor Reviews 21: 345–352.

Germann T and Rüde E (1995) Interleukin‐12. International Archives of Allergy and Immunology 108: 103–112.

Glass WG , Sarisky RT and Del Vecchio AM (2006) Not‐so‐sweet sixteen: The role of IL‐16 in infectious and immune‐mediated inflammatory diseases. Journal of Interferon and Cytokine Research 26: 511–520.

Guo Y , Xu F , Lu T , Duan Z and Zhang Z (2012) Interleukin‐6 signalling pathway in targeted therapy for cancer. Cancer Treatment Reviews 38: 904–910.

Hedrich CM and Bream JH (2010) Cell type‐specific regulation of IL‐10 expression in inflammation and disease. Immunologic Research 47: 185–206.

Heinhuis B , Netea MG , van den Berg WB , Dinarello CA and Joosten LA (2012) Interleukin‐32: a predominantly intracellular proinflammatory mediator that controls cell activation and cell death. Cytokine 60: 321–327.

Heinrich PC , Behrmann I , Haan S et al. (2003) Principles of interleukin (IL)‐6‐type cytokine signalling and its regulation. Biochemical Journal 374: 1–20.

Hershey GK (2003) IL‐13 receptors and signalling pathways. Journal of Allergy and Clinical Immunology 111: 677–690.

Hofmann SR , Rösen-Wolff A , Tsokos GC and Hedrich CM (2012) Biological properties and regulation of IL‐10 related cytokines and their contribution to autoimmune disease and tissue injury. Clinical Immunology 143: 116–127.

Hunter CA (2005) New IL‐12 family members: IL‐23 and IL‐27, cytokines with divergent functions. Nature Reviews Immunology 5: 521–531.

Jones LL and Vignali DA (2011) Molecular interactions within the IL‐6/IL‐12 cytokine/receptor superfamily. Immunologic Research 51: 5–14.

Kishimoto T , Akira S , Narazaki M and Taga T (1995) Interleukin‐6 family of cytokines and gp130. Blood 86: 1243–1254.

Kouro T and Takatsu K (2009) IL‐5‐ and eosinophil‐mediated inflammation: from discovery to therapy. International Immunology 21: 1303–1309.

Koyasu S and Moro K (2011) Type 2 innate immune responses and the natural helper cell. Immunology 132: 475–481.

Langowski JL , Zhang X , Wu L et al. (2006) IL‐23 promotes tumour incidence and growth. Nature 442: 461–465.

Langrish CL , McKenzie BS , Wilson NJ et al. (2004) IL‐12 and IL‐23: master regulators of innate and adaptive immunity. Immunological Reviews 202: 96–105.

Leng RX , Pan HF , Tao JH and Ye DQ (2011) IL‐19, IL‐20 and IL‐24: potential therapeutic targets for autoimmune diseases. Expert Opinion on Therapeutic Targets 15: 119–126.

Li Z , Chen L and Qin Z (2009) Paradoxical roles of IL‐4 in tumor immunity. Cellular and Molecular Immunology 6: 415–422.

Liao W , Lin J‐X and Leonard WJ (2011) IL‐2 family cytokines: new insights into the complex roles of IL‐2 as a broad regulator of T helper cell differentiation. Current Opinion in Immunology 23: 598–604.

Liew FY (2012) IL‐33: a Janus cytokine. Annals of the Rheumatic Diseases 71 (Suppl. 2): i101–i104.

Lin JX , Migone TS , Tsang M et al. (1995) The role of shared receptor motifs and common Stat proteins in the generation of cytokine pleiotropy and redundancy by IL‐2, IL‐4, IL‐7, IL‐13, and IL‐15. Immunity 2: 331–339.

Ma A , Koka R and Burkett P (2006) Diverse functions of IL‐2, IL‐15, and IL‐7 in lymphoid homeostasis. Annual Reviews of Immunology 24: 657–679.

Ma X , Lin WY , Chen Y et al. (2012) Structural basis for the dual recognition of helical cytokines IL‐34 and CSF‐1 by CSF‐1R. Structure 20: 676–687.

Mackall CL , Fry TJ and Gresse RE (2011) Harnessing the biology of IL‐7 for therapeutic application. Nature Reviews Immunology 11: 330–342.

Martinez‐Moczygemba M and Huston DP (2003) Biology of common beta receptor‐signaling cytokines: IL‐3, IL‐5 and GM‐CSF. Journal of Allergy and Clinical Immunology 112: 653–665.

Mehta DS , Wurster AL and Grusby MJ (2004) Biology of IL‐21 and the IL‐21 receptor. Immunological Reviews 202: 84–95.

Mitchell J , Dimov V and Townley RG (2010) IL‐13 and the IL‐13 receptor as therapeutic targets for asthma and allergic disease. Current Opinion in Investigational Drugs 11: 527–534.

Moissec P , Torn T and Kuchroo VK (2009) Interleukin‐17 and type 17 helper T cells. New England Journal of Medicine 361: 888–898.

Mudigonda P , Mudigonda T , Feneran AN et al. (2012) Interleukin‐23 and interleukin‐17: importance in pathogenesis and therapy of psoriasis. Dermatology Online Journal 18(10): 1.

Mueller TD , Zhang JL , Sebald W and Duschl A (2002) Structure, binding, and antagonists in the IL‐4/IL‐13 receptor system. Biochimica et Biophysica Acta 1592: 237–250.

Navarro‐Millan I , Singh JA and Curtis JR (2012) Systematic review of tocilizumab for rheumatoid arthritis: a new biologic agent targeting the interleukin‐6 receptor. Clinical Therapeutics 34: 788–802.

Ning Y and Lenz HJ (2012) Targeting IL‐8 in colorectal cancer. Expert Opinion on Therapeutic Targets 16(5): 491–497.

Nold F , Nold-Petry CA , Zepp JA et al. (2010) IL‐37 is a fundamental inhibitor of innate immunity. Nature Immunology 11: 1014–1022.

Oh CK , Raible D , Geba GP and Molfino NA (2011) Biology of the interleukin‐9 pathway and its therapeutic potential for the treatment of asthma. Inflammation and Allergy – Drug Targets 10: 180–186.

Ouyang W , Rutz S , Crellin NK , Valdez PA and Hymowitz SG (2011) Regulation and functions of the IL‐10 family of cytokines in inflammation and disease. Annual Review of Immunology 29: 71–109.

Palmer MJ , Mahajan VS , Trajman L et al. (2008) Perspectives on the quantitative immunobiology of the IL‐7 signaling network. Cellular and Molecular Immunology 5: 79–89.

Pope RM and Shahara S (2012) Possible roles of IL‐12‐family cytokines in rheumatoid arthritis. Nature Reviews Rheumatology 9(4): 252–256.

Power C and Wells T (1996) Cloning and characterization of human chemokine receptors. Trends in Pharmacological Sciences 17: 209–213.

Putoczki T and Ernst M (2010) More than a sidekick: the IL‐6 family cytokine IL‐11 links inflammation to cancer. Journal of Leukocyte Biology 88: 1109–1117.

Sabat R (2010) IL‐10 family of cytokines. Cytokine and Growth Factor Reviews 21: 315–324.

Sabat R , Grütz G , Warszawska K et al. (2010) Biology of interleukin‐10. Cytokine and Growth Factor Reviews 21: 331–344.

Sahoo M , Ceballos-Olvera I , del Barrio L and Re F (2011) Role of the inflammasome, IL‐1β, and IL‐18 in bacterial infections. Scientific World Journal 11: 2037–2050.

Sasson SC , Zaunders JJ and Kelleher AD (2006) The IL‐7/IL‐7R receptor axis: understanding its central role in T‐cell homeostasis and the challenges facing its utilization as a novel therapy. Current Drug Targets 7: 1571–1582.

Sato T , Terai M , Tamura Y et al. (2011) Interleukin 10 in the tumor microenvironment: a target for anticancer immunotherapy. Immunologic Research 51: 170–182.

Schwertschlag US , Trepicchio WL , Dykstra KH et al. (1999) Hematopoietic, immunomodulatory and epithelial effects of interleukin‐11. Leukemia 13: 1307–1315.

Sims JE and Smith DE (2010) The IL‐1 family: regulators of immunity. Nature Reviews Immunology 10: 89–102.

Sonkoly E , Muller A , Lauerma AI et al. (2006) IL‐31: a new link between T cells and pruritis in atopic skin inflammation. Journal of Allergy and Clinical Immunology 117: 411–417.

Sonnenberg GF , Fouser LA and Artis D (2010) Functional biology of the IL‐22‐IL‐22R pathway in regulating immunity and inflammation at barrier surfaces. Advances in Immunology 107: 1–29.

Spolski R and Leonard WJ (2008) Interleukin‐21: basic biology and implications for cancer and autoimmunity. Annual Review of Immunology 26: 51–79.

Steel JC , Waldmann TA and Morris JC (2012) Interleukin‐15 biology and its therapeutic implications in cancer. Trends in Pharmacological Sciences 33: 35–41.

Stumhofer JS , Tait ED , Quinn WJ 3rd et al. (2010) A role for IL‐27p28 as an antagonist of gp130‐mediated signalling. Nature Immunology 11: 1119–1126.

Sugamura K , Asao H , Kondo M et al. (1995) The common γ‐chain for multiple cytokine receptor. Advances in Immunology 59: 225–277.

Tanaka T and Kishimoto T (2012) Immunotherapeutic implication of IL‐6 blockade. Immunotherapy 4: 87–105.

Tripodi D , Conti F , Rosati M et al. (2012) IL‐36 a new member of the IL‐1 family cytokines. Journal of Biological Regulators and Homeostatic Agents 26: 7–14.

Trivella DB , Ferreira-Júnior JR , Dumoutier L , Renauld JC and Polikarpov I (2010) Structure and function of interleukin‐22 and other members of the interleukin‐10 family. Cellular and Molecular Life Sciences 67: 2909–2935.

Van de Veerdonk FL (2012) IL‐38 binds to the IL‐36 receptor and has biological effects on immune cells similar to the IL‐36 receptor antagonist. Proceedings of the National Academy of Sciences of the USA 109: 3001–3005.

Vignali DAA and Kuchroo VK (2012) IL‐12 family cytokines: immunological playmakers. Nature Immunology 13: 722–728.

Vigne S , Palmer G , Lamacchia C et al. (2011) IL‐36R ligands are potent regulators of dendritic and T cells. Blood 118: 5813–5823.

Waldmann TA (2006) The biology of interleukin‐2 and interleukin‐15: implications for cancer therapy and vaccine design. Nature Reviews Immunology 6: 595–601.

Waugh DJ and Wilson C (2008) The interleukin‐8 pathway in cancer. Clinical Cancer Research 14: 6735–6741.

Weaver CT , Hatton RD , Mangan PR and Harrington LE (2007) IL‐17 family cytokines and expanding diversity of effector T cell lineages. Annual Review of Immunology 25: 821–852.

Whitworth JM and Alvarez RD (2011) Evaluating the role of IL‐12 based therapies in ovarian cancer: a review of the literature. Expert Opinion on Biological Therapy 11: 751–762.

Xu M , Mizoguchi I , Morishima N et al. (2010) Regulation of antitumor immune responses by the IL‐12 family cytokines, IL‐12, IL‐23, and IL‐27. Clinical and Developmental Immunology. DOI: 10.1155/2010/832454.

Xu S and Cao X (2010) Interleukin‐17 and its expanding biological functions. Cellular and Molecular Immunology 7: 164–174.

Yi JS , Cox MA and Zajac AJ (2010) Interleukin‐21: a multifunctional regulator of immunity to infections. Microbes and Infection 12: 1111–1119.

Yuzhalin AE and Kufikhin AG (2012) Interleukin‐12: clinical usage and molecular markers of cancer susceptibility. Growth Factors 30: 176–191.

Zaghi D , Krueger GG and Callis Duffin K (2012) Ustekinumab: a review in the treatment of plaque psoriasis and psoriatic arthritis. Journal of Drugs in Dermatology 11: 160–167.

Zdanov A (2011) Structural analysis of cytokines comprising the IL‐10 family. Cytokine and Growth Factor Reviews 21: 325–330.

Zenewicz LA and Flavell RA (2011) Recent advances in IL‐22 biology. International Immunology 23: 159–163.

Zhang Q , Putheti P , Zhou Q , Liu Q and Gao W (2008) Structures and biological functions of IL‐31 and IL‐31 receptors. Cytokine and Growth Factor Reviews 19: 347–356.

Zhang X , Angkasekwinai P , Dong C and Tang H (2011) Structure and function of interleukin‐17 family cytokines. Protein Cell 2: 26–40.

Further Reading

Aggarwal BB (ed.) (1992) Human Cytokines: Handbook for Basic and Clinical Research, vol. 1. Oxford: Blackwell Science.

Aggarwal BB (ed.) (1996) Human Cytokines: Handbook for Basic and Clinical Research, vol. 2. Oxford: Blackwell Science.

Ibelgaufts H (2013) Cytokines & Cells Online Pathfinder Encyclopaedia (COPE). http://copewithcytokines.de/cope.cgi

Meager T (1998) The Molecular Biology of Cytokines. Chichester, UK: John Wiley.

Mire‐Sluis AR and Thorpe R (eds) (1998) Cytokines. London: Academic Press.

Thomson AW (ed.) (1998) The Cytokine Handbook. London: Academic Press.

Contact Editor close
Submit a note to the editor about this article by filling in the form below.

* Required Field

How to Cite close
Meager, Anthony, and Wadhwa, Meenu(Sep 2013) Interleukins. In: eLS. John Wiley & Sons Ltd, Chichester. http://www.els.net [doi: 10.1002/9780470015902.a0000932.pub3]